Mark A. Young
YOU?
Author Swipe
View article: Expanding the Prostate Cancer Cell Line Repertoire with ACRJ-PC28, an AR-negative Neuroendocrine Cell Line Derived From an African-Caribbean Patient
Expanding the Prostate Cancer Cell Line Repertoire with ACRJ-PC28, an AR-negative Neuroendocrine Cell Line Derived From an African-Caribbean Patient Open
Prostate cancer cell lines from diverse backgrounds are important to addressing disparities in prostate cancer incidence and mortality rates among Black men. ACRJ-PC28 was developed from a transrectal needle biopsy and established via inac…
View article: Activation of FXR by obeticholic acid induces hepatic gene expression of SR-BI through a novel mechanism of transcriptional synergy with the nuclear receptor LXR
Activation of FXR by obeticholic acid induces hepatic gene expression of SR-BI through a novel mechanism of transcriptional synergy with the nuclear receptor LXR Open
The farnesoid X receptor (FXR) is known to regulate the gene expression of SR‑BI, which mediates plasma high‑density lipoprotein (HDL)‑cholesterol uptake. Our previous study demonstrated that the activation of FXR by obeticholic acid (OCA)…
View article: INT-767 improves histopathological features in a diet-induced<i>ob/ob</i>mouse model of biopsy-confirmed non-alcoholic steatohepatitis
INT-767 improves histopathological features in a diet-induced<i>ob/ob</i>mouse model of biopsy-confirmed non-alcoholic steatohepatitis Open
These findings confirm the potential utility of FXR and dual FXR/TGR5 activation as disease intervention strategies in NASH.
View article: Regulation of lipid metabolism by obeticholic acid in hyperlipidemic hamsters
Regulation of lipid metabolism by obeticholic acid in hyperlipidemic hamsters Open
The farnesoid X receptor (FXR) plays critical roles in plasma cholesterol metabolism, in particular HDL-cholesterol (HDL-C) homeostasis. Obeticholic acid (OCA) is a FXR agonist being developed for treating various chronic liver diseases. P…